News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
DR devices today should do more than just provide crystal clear imaging and assist during diagnosis. Hence, the ImageView Software used in DRX Compass offers upgraded cybersecurity
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated
